Muna Qayed
Expertise in
8
conditions

Dr. Muna Qayed

Pediatric Hematology Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
 (730.4 mi)
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
1405 Clifton Rd Ne, 
Atlanta, GA 
 (730.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Muna Qayed is a Pediatric Hematologist Oncology provider in Atlanta, Georgia. Dr. Qayed is highly rated in 8 conditions, according to our data. Her top areas of expertise are Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Chronic Graft Versus Host Disease (cGvHD), Leukemia, and Bone Marrow Transplant. Dr. Qayed is currently accepting new patients.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in GA
Languages Spoken
English
Arabic
Spanish
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Kaiser
  •  UnitedHealthcare
  •  CareSource
  •  Humana

Locations

1405 Clifton Rd Ne, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2025
Intervention Type: Drug
Study Drug: Prednisone
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Other
Study Phase: Not Applicable
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 26, 2024
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2023
Intervention Type: Biological
Study Drug: Virus Specific T-cell infusion
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft Versus Host Disease
A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft Versus Host Disease
Enrollment Status: Completed
Publish Date: January 12, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 10 Less Clinical Trials

115 Total Publications

Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?
Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?
Journal: Pediatric hematology and oncology
Published: November 06, 2024
Similar Doctors
Expertise in
6
conditions
Dr. Carlton D. Dampier
Pediatric Hematology Oncology | Pediatrics
Expertise in
6
conditions
Dr. Carlton D. Dampier
Pediatric Hematology Oncology | Pediatrics
35 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (4.5 mi)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Dampier is highly rated in 6 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
3
conditions
Dr. Shannon L. Meeks
Pediatric Hematology Oncology
Expertise in
3
conditions
Dr. Shannon L. Meeks
Pediatric Hematology Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 mi)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Shannon Meeks is a Pediatric Hematologist Oncology provider in Atlanta, Georgia. Dr. Meeks is highly rated in 3 conditions, according to our data. Their top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Von Willebrand Disease (VWD). Dr. Meeks is currently accepting new patients.

Expertise in
7
conditions
Dr. Vivien A. Sheehan
Pediatric Hematology Oncology | Hematology | Oncology
Expertise in
7
conditions
Dr. Vivien A. Sheehan
Pediatric Hematology Oncology | Hematology | Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 mi)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivien Sheehan is a Pediatric Hematologist Oncology specialist and a Hematologist in Atlanta, Georgia. Dr. Sheehan is highly rated in 7 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Sheehan is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile